Your browser doesn't support javascript.
loading
Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover, Natalie S; Savoldo, Barbara.
Afiliação
  • Grover NS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA. Natalie_grover@med.unc.edu.
  • Savoldo B; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA.
BMC Cancer ; 19(1): 203, 2019 Mar 06.
Article em En | MEDLINE | ID: mdl-30841880
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas. Preclinical studies with CD30-directed CAR-T cells support the feasibility of this approach. Recently, two clinical trials of CD30-directed CAR-T cells in relapsed/refractory CD30+ lymphomas, including Hodgkin lymphoma, have been reported with minimal toxicities noted and preliminary efficacy seen in a proportion of patients. However, improving the persistence and expansion of CAR-T cells is key to further enhancing the efficacy of this treatment approach. Future directions include optimizing the lymphodepletion regimen, enhancing migration to the tumor site, and combination with other immune regulators. Several ongoing and upcoming clinical trials of CD30-directed CAR-T cells are expected to further enhance this approach to treat patients with relapsed and refractory CD30+ lymphomas.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Imunoterapia Adotiva / Antígeno Ki-1 / Receptores de Antígenos Quiméricos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Imunoterapia Adotiva / Antígeno Ki-1 / Receptores de Antígenos Quiméricos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article